Immunosuppression: Today, tomorrow, and withdrawal

Seminars in Liver Disease

Volumn 26, Issue 3, 2006, Pages 201-210

  Hirose, Ryutaro ^a   Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunosuppression; Liver transplant

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTIBODY; ANTIMITOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DIPHENHYDRAMINE; EVEROLIMUS; FINGOLIMOD; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; JANUS KINASE 3 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; UNINDEXED DRUG;

ACNE; ACUTE TOXICITY; ANEMIA; ARTERY THROMBOSIS; BLOOD TOXICITY; BONE DISEASE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CHRONIC TOXICITY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG WITHDRAWAL; DYSPNEA; FEVER; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEPATIC ARTERY; HEPATITIS C; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG EDEMA; LYMPHOCELE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; LYMPHOTOXICITY; OBESITY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RIGOR; SERUM SICKNESS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSPLANTATION TOLERANCE; TREATMENT INDICATION; WOUND HEALING IMPAIRMENT;

ANIMALS; CALCINEURIN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; LIVER TRANSPLANTATION; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION TOLERANCE;

EID: 33746547309     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947290     Document Type: Review

References (39)

1. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-645
2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940
3. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I: taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-726
4. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996;49:209-216
5. Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001;7:401-408
6. Legendre C, Campistol JM, Squifflet JP, et al. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 2003;35:151S-153S
7. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003;76:375-382
8. Eason JD, Blazek J, Mason A, et al. Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplant Proc 2001;33:1470-1471
9. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003;75:1396-1399
10. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-131
11. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142
12. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001;7:220-225
13. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-1287
14. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000;69:307-311
15. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729
16. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002;2:898-903
17. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-1025
18. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets 2004;8:613-629
19. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-878
20. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in non-human primates. Transplantation 2005;79:791-801
21. Birsan T, Dambrin C, Klupp J, et al. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 2003;11:163-167
22. Bilolo KK, Ouyang J, Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003;75:1881-1887
23. Yamamoto S, Okuda T, Yamasaki K, et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. Transplant Proc 2005;37:126-129
24. Joshi A, Bauer R, Kuebler P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 2006;46:10-20
25. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006;6:27-36
26. Corbascio M, Ekstrand H, Osterholm C, et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol 2002;10:55-61
27. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003;19:503-514
28. Knechtle SJ, Pirsch JD, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722-730
29. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003;76:120-129
30. Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr Transplant 2004;8:9-21
31. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443-453
32. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-1049
33. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212
34. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-1821
35. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-11105
36. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438
37. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794
38. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-781
39. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005;174:542-550